Eleonora De Matteis, Federico De Santis, Raffaele Ornello, Bruno Censori, Valentina Puglisi, Luisa Vinciguerra, Alessia Giossi, Pietro Di Viesti, Vincenzo Inchingolo, Giovanni Matteo Fratta, Marina Diomedi, Maria Rosaria Bagnato, Silvia Cenciarelli, Chiara Bedetti, Chiara Padiglioni, Tiziana Tassinari, Valentina Saia, Alessandro Russo, Marco Petruzzellis, Domenico Maria Mezzapesa, Martina Caccamo, Giuseppe Rinaldi, Alessandra Bavaro, Maurizio Paciaroni, Maria Giulia Mosconi, Matteo Foschi, Pietro Querzani, Francesco Muscia, Serena Gallo Cassarino, Paolo Candelaresi, Antonio De Mase, Maria Guarino, Letizia Maria Cupini, Enzo Sanzaro, Andrea Zini, Salvatore La Spada, Carmela Palmieri, Federica Nicoletta Sepe, Simone Beretta, Cristina Paci, Emanuele Alessandro Caggia, Maria Vittoria De Angelis, Laura Bonanni, Gino Volpi, Rossana Tassi, Francesca Pistoia, Umberto Scoditti, Agnese Tonon, Giovanna Viticchi, Giampietro Ruzza, Patrizia Nencini, Anna Cavallini, Danilo Toni, Stefano Ricci, Simona Sacco
BACKGROUND: Randomized controlled trials (RCTs) proved that short-term (21-90 days) dual antiplatelet therapy (DAPT) reduces the risk of early ischemic recurrences after a noncardioembolic minor stroke or high-risk transient ischemic attack (TIA) without substantially increasing the hemorrhagic risk. We aimed at understanding whether and how real-world use of DAPT differs from RCTs. METHODS: READAPT (Real-Life Study on Short-Term Dual Antiplatelet Treatment in Patients With Ischemic Stroke or TIA) is a prospective cohort study including >18-year-old patients treated with DAPT after a noncardioembolic minor ischemic stroke or high-risk TIA from 51 Italian centers...
March 23, 2023: Stroke; a Journal of Cerebral Circulation